Here’s a startling fact: Melanoma has been the leading cause of skin cancer malpractice lawsuits for nearly a century, with devastating consequences in nearly one-third of cases. But here’s where it gets controversial—while melanoma dominates these lawsuits, the most common allegation isn’t about treatment gone wrong, but rather a failure or delay in diagnosis. This raises a critical question: Are physicians missing the mark when it comes to early detection, and what does this mean for patient outcomes?
In a groundbreaking study spanning 95 years (1930–2025), researchers analyzed 188 medicolegal cases involving skin cancer using the LexisNexis legal database. The focus? Physician-related malpractice cases where the litigation centered on the diagnosis or management of skin malignancies. The findings are eye-opening—and not just for dermatologists. Family physicians, not dermatologists, were the most frequently named defendants, accounting for 27.5% of cases. This might surprise many, as dermatologists are often considered the go-to specialists for skin cancer. So, why are family doctors bearing the brunt of these lawsuits?
Let’s break it down. Melanoma accounted for nearly half (49.5%) of all litigated cases, followed by squamous cell carcinoma (21.6%) and basal cell carcinoma (14.2%). What’s alarming is that death was reported in 29.8% of cases, and metastatic disease in 39.9%. These aren’t just numbers—they represent lives lost and families shattered. And this is the part most people miss: the leading allegation wasn’t about botched surgeries or incorrect treatments, but rather a failure or delay in diagnosis (38.1%). This begs the question: Are we doing enough to educate all physicians, not just dermatologists, on the early signs of melanoma?
The study also revealed that private practices were the most common setting for these cases (59.7%), with New York and California leading the charge in terms of case volume. Among the 109 closed cases, only 5.5% resulted in plaintiff verdicts, while defense verdicts dominated at 55.0%. Plaintiff awards ranged from $10,000 to a staggering $4.25 million, highlighting the financial and reputational stakes for physicians.
But here’s the kicker: The study likely underestimates the true burden of malpractice, as it only includes published court decisions and excludes settlements or unreported claims. This means the problem could be even more widespread than we realize. So, what’s the takeaway? As the authors point out, this analysis isn’t just about assigning blame—it’s a pragmatic look at the real-world risks physicians face, from legal battles to psychological stress, regardless of the case outcome.
Led by Dr. Ghassan Barnawi of McGill University and published in the Journal of the American Academy of Dermatology, this study serves as a wake-up call. It challenges us to rethink how we approach skin cancer detection and management across all levels of healthcare. Is it time to rethink training protocols for family physicians? Or should we be pushing for earlier referrals to dermatologists? We want to hear from you—do these findings align with your experiences, or do they challenge your assumptions? Let’s start a conversation in the comments below.
